Skip to main content Accessibility help
×
Home

Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: Randomised controlled non-inferiority trial

  • Marloes J. Huijbers (a1), Philip Spinhoven (a2), Jan Spijker (a3), Henricus G. Ruhé (a4), Digna J. F. van Schaik (a5), Patricia van Oppen (a5), Willem A. Nolen (a4), Johan Ormel (a4), Willem Kuyken (a6), Gert Jan van der Wilt (a7), Marc B. J. Blom (a8), Aart H. Schene (a1), A. Rogier T. Donders (a7) and Anne E. M. Speckens (a1)...

Abstract

Background

Mindfulness-based cognitive therapy (MBCT) and maintenance antidepressant medication (mADM) both reduce the risk of relapse in recurrent depression, but their combination has not been studied.

Aims

To investigate whether MBCT with discontinuation of mADM is non-inferior to MBCT+mADM.

Method

A multicentre randomised controlled non-inferiority trial (ClinicalTrials.gov: NCT00928980). Adults with recurrent depression in remission, using mADM for 6 months or longer (n = 249), were randomly allocated to either discontinue (n = 128) or continue (n = 121) mADM after MBCT. The primary outcome was depressive relapse/recurrence within 15 months. A confidence interval approach with a margin of 25% was used to test non-inferiority. Key secondary outcomes were time to relapse/recurrence and depression severity.

Results

The difference in relapse/recurrence rates exceeded the non-inferiority margin and time to relapse/recurrence was significantly shorter after discontinuation of mADM. There were only minor differences in depression severity.

Conclusions

Our findings suggest an increased risk of relapse/recurrence in patients withdrawing from mADM after MBCT.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: Randomised controlled non-inferiority trial
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: Randomised controlled non-inferiority trial
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: Randomised controlled non-inferiority trial
      Available formats
      ×

Copyright

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.

Corresponding author

Marloes Johanna Huijbers, Department of Psychiatry, Radboud University Medical Center, Reinier Postlaan 10, 6525 GC Nijmegen, The Netherlands. Email: marloes.huijbers@radboudumc.nl

Footnotes

Hide All

This research project was an independent study funded by ZonMW, The Netherlands Organization for Health Research and Development (Grant no. 170992903, awarded to A.E.M.S.).

Declaration of interest

None.

Footnotes

References

Hide All
1 Richards, D. Prevalence and clinical course of depression: a review. Clin Psychol Rev 2011; 31: 1117–25.
2 Kaymaz, N, van Os, J, Loonen, AJ, Nolen, WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008; 69: 1423–36.
3 Borges, S, Chen, YF, Laughren, TP, Temple, R, Patel, HD, David, PA, et al. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry 2014; 75: 205–14.
4 Viguera, AC, Baldessarini, RJ, Friedberg, J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293306.
5 American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd edn. APA, 2010.
6 National Institute for Health and Care Excellence. Depression in Adults: The Treatment and Management of Depression in Adults (CG90). National Institute for Health and Care Excellence, 2009.
7 Bockting, CL, ten Doesschate, MC, Spijker, J, Spinhoven, P, Koeter, MW, Schene, AH. Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 2008; 77: 1726.
8 Dobson, KS, Hollon, SD, Dimidjian, S, Schmaling, KB, Kohlenberg, RJ, Gallop, RJ, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol 2008; 76: 468–77.
9 van Schaik, D, Klijn, A, van Hout, H, van Marwijk, H, Beekman, A, de Haan, M, et al. Patients' preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiat 2004; 26: 184–9.
10 Segal, ZV, Williams, JMG, Teasdale, JD. Mindfulness-Based Cognitive Therapy for Depression, 2nd edn. Guilford Press, 2012.
11 Kabat-Zinn, J. Full Catastrophe Living: Using the Wisdom of your Body and Mind to Face Stress, Pain, and Illness. Bantam Books, 2013.
12 Beck, AT, Rush, AJ, Shaw, BF, Emery, G. Cognitive Therapy of Depression. Guilford Press, 1979.
13 Piet, J, Hougaard, E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin Psychol Rev 2011; 31: 1032–40.
14 Spijker, J, Bockting, CLH, Meeuwissen, JAC, Vliet, IM van, Emmelkamp, PMG, Hermens, MLM, et al. Multidisciplinaire Richtlijn Depressie (Derde Revisie). Richtlijn voor de Diagnostiek, Behandeling en Begeleiding Van Volwassen Patiënten met een Depressieve Stoornis [Multidisciplinary Guidelines Depression (3rd revision). Guidelines for the Diagnosis, Treatment and Monitoring of Patients with Depressive Disorder]. Trimbos-institute, 2013.
15 Kuyken, W, Byford, S, Taylor, RS, Watkins, E, Holden, E, White, K, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008; 76: 966–78.
16 Segal, ZV, Bieling, P, Young, T, MacQueen, G, Cooke, R, Martin, L, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 2010; 67: 1256–64.
17 Kuyken, W, Hayes, R, Barrett, B, Byng, R, Dalgleish, T, Kessler, D, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. Lancet 2015; 386: 6373.
18 Huijbers, MJ, Spijker, J, Donders, AR, van Schaik, DJ, van Oppen, P, Ruhe, HG, et al. Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study. BMC Psychiatry 2012; 12: 125.
19 Huijbers, MJ, Spinhoven, P, Spijker, J, Ruhe, HG, van Schaik, DJ, van Oppen, P, et al. Adding mindfulness-based cognitive therapy to maintenance antidepressant medication for prevention of relapse/recurrence in major depressive disorder. Randomised controlled trial. J Affect Disord 2015; 187: 5461.
20 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, revised) (DSM-IV-TR). APA, 2000.
21 First, MB, Gibbon, M, Spitzer, RL, Williams, JBW. User Guide for the Structured Clinical Interview for DSM-IV Axis 1 Disorders. American Psychiatric Association, 1996.
22 Akkerhuis, GW. Vertaling IDS. H.C. Rümke Groep, 1997.
23 Rush, AJ, Gullion, CM, Basco, MR, Jarrett, RB, Trivedi, MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477–86.
24 Segal, ZV, Williams, JMG, Teasdale, JD. Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Relapse Prevention. Guilford Press, 2002.
25 Crane, RS, Eames, C, Kuyken, W, Hastings, RP, Williams, JMG, Bartley, T, et al. Development and validation of the mindfulness-based interventions–teaching assessment criteria (MBI:TAC). Assessment 2013; 20: 681–8.
26 Teasdale, JD, Segal, ZV, Williams, JMG, Ridgeway, VA, Soulsby, JM, Lau, MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000; 68: 615–23.
27 Landis, JR, Koch, GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159–74.
28 Trivedi, MH, Rush, AJ, Ibrahim, HM, Carmody, TJ, Biggs, MM, Suppes, T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 7382.
29 The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28: 551–8.
30 EMA Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 2001; 52: 223.
31 Food and Drug Administration. Draft Guidance for Industry on Non-Inferiority Clinical Trials. FDA, 2010 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf).
32 Hardeveld, F, Spijker, J, De Graaf, R, Nolen, WA, Beekman, AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010; 122: 184–91.
33 Cuijpers, P, Sijbrandij, M, Koole, SL, Andersson, G, Beekman, AT, Reynolds, CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 2014; 13: 5667.
34 Guidi, J, Fava, GA, Fava, M, Papakostas, GI. Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med 2011; 41: 321–31.
35 Fava, GA, Ruini, C, Rafanelli, C, Finos, L, Conti, S, Grandi, S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004; 161: 1872–6.
36 Haddad, PM, Anderson, IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 2007; 13: 447–57.
37 Lejoyeux, M, Ades, J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997; 58 (suppl 7): 11–5.
38 Rosenbaum, JF, Fava, M, Hoog, SL, Ascroft, RC, Krebs, WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 7787.
39 Verbeek-Heida, PM, Mathot, EF. Better safe than sorry—why patients prefer to stop using selective serotonin reuptake inhibitor (SSRI) antidepressants but are afraid to do so: results of a qualitative study. Chronic Illn 2006; 2: 133–42.
40 Goldberg, D. Plato versus Aristotle: categorical and dimensional models for common mental disorders. Compr Psychiatry 2000; 41: 813.
41 Kraemer, HC, Noda, A, O'Hara, R. Categorical versus dimensional approaches to diagnosis: methodological challenges. J Psychiatr Res 2004; 38: 1725.
Type Description Title
PDF
Supplementary materials

Huijbers et al. supplementary material
Supplementary Table S1-S2

 PDF (48 KB)
48 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: Randomised controlled non-inferiority trial

  • Marloes J. Huijbers (a1), Philip Spinhoven (a2), Jan Spijker (a3), Henricus G. Ruhé (a4), Digna J. F. van Schaik (a5), Patricia van Oppen (a5), Willem A. Nolen (a4), Johan Ormel (a4), Willem Kuyken (a6), Gert Jan van der Wilt (a7), Marc B. J. Blom (a8), Aart H. Schene (a1), A. Rogier T. Donders (a7) and Anne E. M. Speckens (a1)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *